Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for Endothelial Function in CKD (PENNY)
NCT01680198Phase 3Completed
- Sponsor
- Fondazione Monasterio
- Start
- Jun 2011
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paricalcitol in chronic kidney disease (CKD), sponsored by Fondazione Monasterio. Primary endpoint: Flow Mediated Dilatation at 12 weeks. Started Jun 2011; status: completed.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01680198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01680198.